ArticleCardiology research2025
Article in Cardiology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heart failure (HF) is a major cause of global morbidity and mortality. Patients with acute decompensated chronic HF (ad-CHF) usually have more comorbidities, whereas those with Methods: An ambispective study was conducted at a tertiary hospital in Colombia, including 780 patients hospitalized for acute HF. Patients were classified as dn-AHF or ad-CHF, and sociodemographic, clinical, and in-hospital outcomes were compared using bivariate analysis. A Firth penalized logistic regression model was used to assess the association between dn-AHF and in-hospital mortality. Results: Of these patients, 39.2% had dn-AHF, and 60.8% had ad-CHF. Median ages were 67 (interquartile range (IQR): 56 - 76) and 66 (IQR: 55 - 79) years, respectively. Both groups had a predominance of reduced left ventricular ejection fraction, with median values of 30% in ad-CHF and 34% in dn-AHF. Ad-CHF patients had more comorbidities, whereas dn-AHF patients showed higher rates of cardiac and non-cardiac complications. Intensive care unit (ICU) admission rates were similar, the need for invasive mechanical ventilation (P < 0.001) and the occurrence of infections (P = 0.049) were significantly more frequent in patients with dn-AHF. In-hospital mortality was higher in dn-AHF than ad-CHF (9.8% vs. 5.5%, P = 0.023). After adjustment, dn-AHF remained independently associated with greater in-hospital mortality (odds ratio (OR): 1.87; 95% confidence interval (CI): 1.07 - 3.31; P = 0.029). Conclusions: Patients with dn-AHF experienced more in-hospital complications and higher mortality than those with ad-CHF, despite similar ICU admission rates and fewer comorbidities. These results highlight the prognostic importance of dn-AHF and underscore the need for early identification, vigilant monitoring, and phenotype-specific management from admission to improve outcomes, particularly among patients with reduced ejection fraction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.